# Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

> **NCT07741448** · PHASE2 · RECRUITING · sponsor: **Zhiquan Hu** · enrollment: 54 (estimated)

## Conditions studied

- UTUC

## Interventions

- **DRUG:** Trastuzumab Rezetecan
- **DRUG:** Gemcitabine
- **PROCEDURE:** Radical nephroureterectomy

## Key facts

- **NCT ID:** NCT07741448
- **Lead sponsor:** Zhiquan Hu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2028-08-15
- **Final completion:** 2029-08-15
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741448, "Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*